Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol
- 1 January 1986
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 16 (5), 435-447
- https://doi.org/10.3109/00498258609050250
Abstract
1. The contribution of debrisoquine polymorphism to the metabolism and action of β-adrenoceptor antagonists (β-blockers) varies widely between drugs. 2. Oxidation phenotype is a major determinant of the metabolism, pharmacokinetics and some of the pharmacological actions of metoprolol, bufuralol and timolol. The poor metabolizer phenotype is associated with an increased area under the plasma drug concentration vs. time curve, a prolongation of elimination half-life and a more intense and sustained β-blockade. 3. The stereoselective metabolism of metoprolol also displays phenotypic differences, which should be taken into account when interpreting plasma concentration vs. response relationships. 4. Studies in vivo and in vitro have identified some of the metabolic pathways which are subject to this defect, namely the α-hydroxylation and the O-demethylation of metoprolol and the 1′-hydroxylation of bufuralol. 5. In contrast, the pharmacokinetics and pharmacodynamics of propranolol, which is also extensively oxidized, are not related to debrisoquine polymorphism, although 4′-hydroxypropranolol formation is deficient in the poor metabolizer phenotype. 6. The disposition of atenolol, which is almost completely eliminated unchanged by renal and faecal excretion, is independent of oxidation phenotype. 7. If standard doses of some β-blockers are used in poor metabolizers, these patients may be susceptible to concentration-related adverse reactions and they may also require lower and less frequent dosing for control of angina pectoris.This publication has 33 references indexed in Scilit:
- Genetic polymorphism in drug oxidation: In vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1′-hydroxylase activitiesBiochemical Pharmacology, 1985
- Relationships among timolol doses, plasma concentrations and beta- adrenoceptor blocking activity.British Journal of Clinical Pharmacology, 1982
- Defective hydroxylation of bufuralol associated with side‐effects of the drug in poor metabolisers [letter]British Journal of Clinical Pharmacology, 1982
- HIGH PLASMA CONCENTRATIONS OF β-RECEPTOR BLOCKING DRUGS AND DEFICIENT DEBRISOQUINE HYDROXYLATIONThe Lancet, 1982
- The genetic controlof bufuralol metabolisminmanEuropean Journal of Drug Metabolism and Pharmacokinetics, 1982
- Timolol pharmacokinetics and effects on heart rate and blood pressure after acute and chronic administrationEuropean Journal of Clinical Pharmacology, 1979
- Determination of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detectionJournal of Mass Spectrometry, 1976
- Metabolism of metoprolol‐(3H) in man, the dog and the ratActa Pharmacologica et Toxicologica, 1975
- Effect of route of administration on the relationship between β‐adrenergic blockade and plasma propranolol levelClinical Pharmacology & Therapeutics, 1972
- Plasma Propranolol Levels in the Quantitative Assessment of -adrenergic Blockade in ManBMJ, 1970